Peter A. Thompson, a director at Sionna Therapeutics (SION +2.89%), executed the indirect sale of 55,345 shares valued at approximately $2.47 million on April 17 and 18, 2026. This transaction, disclosed via an SEC Form 4 filing, represents about 2% of Thompson’s indirect holdings and occurred at a weighted average price of $44.67, significantly above the market price of $38.11 at the time.
This sale comes amid a remarkable year for Sionna, with shares soaring 215% as the company advances its biopharmaceutical treatments for cystic fibrosis. The timing of the sale suggests strategic portfolio management rather than a shift in confidence, particularly as Sionna prepares for crucial Phase 2a data from its PreciSION CF trial this summer, which could significantly impact market expectations.
Investors should closely monitor Sionna’s upcoming trial results, as the company’s innovative approach to CFTR modulation and solid financial footing—boasting $310 million in cash—position it well for further developments and potential stock performance shifts.
Source: fool.com